Intermediatebiotechnology

Huntington's Disease Genetics

Overview

Huntington's disease is the classic autosomal dominant neurodegenerative disorder: CAG trinucleotide repeat expansion in HTT (chromosome 4) beyond 36 repeats produces toxic mutant huntingtin, killing striatal neurons. Anticipation (earlier onset in later generations) reflects repeat expansion in transmission. Onset typically 30-50; predictive testing raises profound ethical issues. Gene-silencing therapies are in trials.

Learning objectives

  • Explain the CAG repeat mechanism
  • Describe anticipation
  • Explain dominant inheritance and recurrence
  • Discuss predictive testing ethics

The repeat expansion

HTT exon 1 CAG repeats: <=26 normal, 27-35 mutable intermediate, 36-39 reduced penetrance, >=40 full penetrance. Expanded polyglutamine tract misfolds huntingtin into toxic aggregates; striatal medium spiny neurons die first (chorea, then cognitive/psychiatric decline).

36: the threshold

Repeat length predicts onset age inversely: longer repeats, earlier disease.

Anticipation

Repeats expand during gametogenesis (especially paternal transmission): children inherit longer repeats and earlier onset than parents. Explains worsening family histories. Juvenile Huntington's (onset <20) usually comes from paternal transmission of large expansions.

Paternal expansion bias

Spermatogenesis expands repeats more than oogenesis: fathers transmit anticipation more often.

Dominant inheritance

One expanded allele suffices: 50% risk to each child of an affected parent. Homozygotes are not worse (true dominant). De novo expansions from intermediate alleles occur. Predictive testing of at-risk adults: uptake only ~10-20% despite availability since 1993.

Why so few test?

No preventive treatment existed for decades: many prefer not to know a certain future.

Therapeutic horizon

Antisense oligonucleotides (tominersen) and RNAi lower huntingtin; results mixed. CRISPR excision of repeats in trials. Genetic modifiers (FAN1, MSH3) affecting repeat instability are new drug targets. Hope now justifies testing for many.

Lowering huntingtin

The therapeutic strategy: less mutant protein, slower neurodegeneration.

Key points

  • CAG >= 36 in HTT: toxic polyglutamine kills striatal neurons
  • Anticipation: paternal repeat expansion -> earlier onset
  • AD: 50% per child; predictive testing uptake low without treatment
  • Huntingtin-lowering therapies in trials

Common misconceptions

✗ Myth: Huntington's skips generations.

✓ Truth: It cannot skip: apparent skips are early death, misdiagnosis, or non-paternity. Reduced-penetrance alleles (36-39) can appear to skip.

✗ Myth: If the repeat is 30, you're safe forever.

✓ Truth: Intermediate alleles (27-35) can expand into disease range in the next generation.

Practice questions

Q1. Huntington's disease is caused by
  1. A deletion
  2. CAG repeat expansion in HTT
  3. Trisomy
  4. A virus
Answer: B.

Polyglutamine expansion beyond 36 repeats.

Q2. Anticipation in Huntington's results from
  1. Better diagnosis
  2. Repeat expansion during transmission, especially paternal
  3. Environment
  4. Imprinting
Answer: B.

Longer repeats in children cause earlier onset.

Q3. Each child of an affected parent has a ___ risk
  1. 25%
  2. 50%
  3. 100%
  4. 0%
Answer: B.

Autosomal dominant: one mutant allele suffices.

Click a question to reveal the answer and explanation.

Frequently asked questions

Why the striatum first?

Medium spiny neurons are selectively vulnerable to mutant huntingtin: the basis of chorea.

What is Venezuela's role?

The Lake Maracaibo kindred (thousands affected) enabled the 1983 linkage mapping and 1993 gene discovery.

Should children be tested?

Guidelines say no predictive testing of minors for adult-onset untreatable conditions: autonomy preserved.